Hologic (NASDAQ: HOLX) and Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for Hologic and Invivo Therapeutics Holdings Corp, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hologic 0 4 9 0 2.69
Invivo Therapeutics Holdings Corp 0 1 0 0 2.00

Hologic currently has a consensus price target of $48.62, indicating a potential upside of 29.92%. Invivo Therapeutics Holdings Corp has a consensus price target of $6.00, indicating a potential upside of 380.00%. Given Invivo Therapeutics Holdings Corp’s higher possible upside, analysts clearly believe Invivo Therapeutics Holdings Corp is more favorable than Hologic.

Profitability

This table compares Hologic and Invivo Therapeutics Holdings Corp’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Hologic 25.65% 23.18% 7.39%
Invivo Therapeutics Holdings Corp N/A -96.88% -80.44%

Insider and Institutional Ownership

94.4% of Hologic shares are owned by institutional investors. 0.8% of Hologic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Hologic and Invivo Therapeutics Holdings Corp’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Hologic $2.98 billion 3.52 $1.01 billion $2.68 13.96
Invivo Therapeutics Holdings Corp N/A N/A -$25.77 million N/A N/A

Hologic has higher revenue and earnings than Invivo Therapeutics Holdings Corp.

Summary

Hologic beats Invivo Therapeutics Holdings Corp on 9 of the 10 factors compared between the two stocks.

Hologic Company Profile

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

Invivo Therapeutics Holdings Corp Company Profile

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.